Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
about
Constituents of Saffron (Crocus sativus L.) as Potential Candidates for the Treatment of Anxiety Disorders and SchizophreniaThe translational study of apathy-an ecological approachConsiderations for resting state functional MRI and functional connectivity studies in rodentsNegative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotionDrug models of schizophreniaTemporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brainNeuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic Signaling in MiceAnimal models of gene-environment interaction in schizophrenia: A dimensional perspective.Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype.Molecular substrates of schizophrenia: homeostatic signaling to connectivityDeveloping treatments for cognitive deficits in schizophrenia: the challenge of translation.Mouse models of gene-environment interactions in schizophrenia.Pre-clinical models of neurodevelopmental disorders: focus on the cerebellumInteraction of genotype and environment: effect of strain and housing conditions on cognitive behavior in rodent models of schizophrenia.Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research.Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: translational evidence from the stress-resilient Ahi1 knockout mouse.A virtual reality task based on animal research - spatial learning and memory in patients after the first episode of schizophrenia.Ketamine and phencyclidine: the good, the bad and the unexpected.Altered functional brain network connectivity and glutamate system function in transgenic mice expressing truncated Disrupted-in-Schizophrenia 1AMIGO-Kv2.1 Potassium Channel Complex Is Associated With Schizophrenia-Related Phenotypes.Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations.Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.KCNH2-3.1 expression impairs cognition and alters neuronal function in a model of molecular pathology associated with schizophrenia.Future viable models of psychiatry drug discovery in pharma.Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological "minefield".Peptide POP inhibitors for the treatment of the cognitive symptoms of schizophrenia.Animal models for predicting the efficacy and side effects of antipsychotic drugs.Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Modelling the genetic contribution to mental illness: a timely end for the psychiatric rodent?Novel treatment strategies for schizophrenia from improved understanding of genetic risk.Recent genetic findings in schizophrenia and their therapeutic relevanceFunctional brain connectivity phenotypes for schizophrenia drug discovery.The thalamic reticular nucleus: a functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery.Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of SchizophreniaLoss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.Using Intermediate Cognitive Endpoints to Facilitate Translational Research in Psychosis.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Altering the course of schizophrenia: progress and perspectives.New drug developments in psychosis: Challenges, opportunities and strategies.
P2860
Q26767403-56BBD372-6AA0-4619-8948-CE6FA5F9E029Q26781597-8C1CDA22-236F-4BCE-B59B-3C49C28DF451Q26795539-ACBAADE8-1540-448F-A977-583242AD89A9Q27325106-1831951D-A5D6-4D64-B678-EAE37B6B8B02Q28084198-AA72B9B4-6CFF-4CB5-BF01-AF230C49FEC6Q28543523-13231F4F-7599-4F4B-8C0F-DD68A51B0768Q29541297-43F9059B-828D-4D17-AB42-370E841790FBQ30367009-CDD4AF35-997D-4A4B-A2B1-17D1708CF985Q30371206-719CC48A-87C0-4833-A8C1-0732842DF785Q30383611-1E276B89-158D-434E-8EE6-A984389F556DQ30396775-240ABA96-84E0-448B-8912-CCAF62AABE79Q30432026-0833A44E-59D2-46BC-B17B-E074E0A23176Q30436913-DDE15178-FD41-45AA-8041-14FCD475A01AQ30451282-75C67D5A-CC34-428D-BC91-28361AEECF4DQ30582343-5896E93D-6FBE-4690-8B19-F6000065F535Q30853401-27932280-5459-4035-9900-4CF577D2DBCEQ33668339-E79A5B7A-D6F1-47BC-B93F-0C2B729C4DFDQ34480719-04B0A347-89B4-46BE-8C52-29AB42AB120EQ35753205-BB7FC2FD-5C8B-44C7-97C7-1C43C844E0E9Q36377899-BF9BF6EC-226A-40F5-B117-6B3519D7A366Q36678412-5250962D-1481-4981-9636-6DF5007703ECQ36990973-3827CD2C-5334-4EEB-A257-8E253596D982Q37165829-34B57A93-A71F-4AAE-AB57-3D0247CDA5F7Q38080006-D5394A1D-8103-4971-9351-1D1021651E90Q38110180-14D920FC-3504-4BCD-9944-9E54F4A3BD95Q38136309-66505BC8-0DEE-4FD1-982C-7E32885DE0D2Q38165756-B83AC5EE-90EB-4086-BA9F-B4BFAC8772F5Q38209355-F39C4CF0-71CE-46D9-A5E8-090036197204Q38214995-8D3A6470-9AF2-4177-AC3F-A90C3A253A96Q38241786-13D5D242-F4B3-483D-876A-A331CA580518Q38260258-4A554A29-64F9-4CFB-A07D-D2265347273EQ38310759-93BAE686-2CD2-4074-B96A-831950C877B1Q38317401-424D6FCF-0D85-468B-9715-2D08B1C49C4FQ38568415-133ED0B7-1FFF-40B9-B45D-A4682D0545FDQ38629841-A33E9D5C-B8E9-463A-96FD-98779FDC5F0BQ38669576-BB8F67C3-4177-4621-9020-C64958D4399AQ38670526-376EB6AD-9FDB-482F-B91B-460091A95EF4Q38699013-CE3259DF-CCFF-4732-8649-13F637609636Q38759421-2E56F40E-28D8-43FB-9E0C-0B13B6F92D49Q38926246-AD08B28F-FDAC-4838-A949-3A573C514718
P2860
Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Advancing schizophrenia drug d ...... bridge the translational gap.
@ast
Advancing schizophrenia drug d ...... bridge the translational gap.
@en
Advancing schizophrenia drug d ...... bridge the translational gap.
@nl
type
label
Advancing schizophrenia drug d ...... bridge the translational gap.
@ast
Advancing schizophrenia drug d ...... bridge the translational gap.
@en
Advancing schizophrenia drug d ...... bridge the translational gap.
@nl
prefLabel
Advancing schizophrenia drug d ...... bridge the translational gap.
@ast
Advancing schizophrenia drug d ...... bridge the translational gap.
@en
Advancing schizophrenia drug d ...... bridge the translational gap.
@nl
P2093
P356
P1476
Advancing schizophrenia drug d ...... bridge the translational gap.
@en
P2093
Brian Morris
Catherine Winchester
Judith Pratt
Neil Dawson
P2888
P304
P356
10.1038/NRD3649
P577
2012-06-22T00:00:00Z
P5875
P6179
1051061737